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Abstract Protein-tyrosine phosphatases (PTPs) are key reg-
ulators of the insulin receptor signal transduction pathway. We 
have performed a detailed analysis of PTP expression in the 
major human insulin target tissues or cells (liver, adipose tissue, 
skeletal muscle and endothelial cells). To obtain a representative 
picture, all tissues were analyzed by PCR using three différent 
primer sets corresponding to conserved regions of known PTPs. 
A total of 24 different PTPs were identified. A multiprobe 
RNase protection assay was developed to obtain a semi-
quantitative measure of the expression levels of selected PTPs. 
Surprisingly, PTP-LAR, previously suggested to be a major 
regulator of the insulin receptor tyrosine kinase, was expressed in 
extremely low levels in skeletal muscle, whereas the related 
receptor-type PTP-o and PTP-ot were expressed in relatively 
high levels in all four tissues. The low levels of LAR PTP mRNA 
in skeletal muscle were further confirmed by Northern blot 
analysis. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Receptor tyrosine kinases, including the insulin receptor, 
are tightly regulated by counter-acting protein-tyrosine phos-
phatases (PTPs) [1]. Thus, several studies have shown that the 
insulin receptor is dephosphorylated by PTPs during internal-
ization following insulin binding with concomitant activation 
and autophosphorylation [2-4]. While the insulin receptor ty-
rosine kinase is negatively regulated by PTP-mediated dephos-
phorylation, other insulin signalling processes seem to be pos-
itively regulated by members of the PTP family, e.g. SHP-2 
[5]. 
The intimate relationship between the insulin receptor and 
PTPs is further evidenced by in vitro studies. Thus, insulin 
treatment of the well-differentiated rat hepatoma cell line Fao 
leads to increased PTP activity in the particulate fraction, but 
a decrease in the cytosolic fraction [6]. In another rat hepato-
ma cell line, McA-RH7777, the insulin signalling is augmented 
by antisense inhibition of PTP-LAR [7]. 
Little is known about the identity of the PTPs involved in 
insulin receptor (IR) regulation. We hypothesize that: (a) the 
same PTPs will be involved in IR regulation in the major 
insulin target tissues, (b) these PTPs are significant contribu-
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tors to the overall PTP activity in the tissues, and (c) these 
PTPs belong to the class of 'classical' PTPs which can be 
identified with degenerate PCR primers corresponding to con-
served regions of known PTPs. Thus, a detailed analysis of 
PTP expression in these tissues should provide essential infor-
mation for identification of the insulin receptor associated 
PTPs. In the present study, using PCR we have analyzed 
the expression pattern of PTPs in the major insulin target 
tissues: skeletal muscle, liver, adipose tissue and endothelial 
cells. This analysis was followed by semi-quantitative assess-
ment of the expression levels in normal tissue using the mul-
tiprobe RNAse protection assay approach. 
2. Materials and methods 
2.1. PCR 
Five degenerate PTP specific PCR primers were constructed. The 
two sense primers: Fl: 5'-CGGGATCCA(C/T)TT(C/T)TGG(A/C/G) 
(A/G)(A/G)ATG(A/G) T(T/C/G/A)TGG-3' and F2: 5'-CGGGATC-
CA(C/T)TT(C/T)TGG(C/A)(T/G/A)(T/G)ATG(A/G)T(T/C/A)TGG-
(G/QA-3' correspond to the PTP amino acid consensus sequence 
FWXMXW. 
The three antisense primers: Bl: 5'-CGGAATTCC(T/C/G/A)A-
(C/T)(A/G/T)CC(A/T/C)GC(A/G)CT(G/A)CA(G/A)TG-3', B2: 5'-
CGGAATTCGCCC(A/G)A(C/T)(T/C/G/A)GC(T/C/G/A)GC(T/C/G/ 
A)CT(G/A)CA-(G/A)TG-3', and B3: 5'-GGTGTTCTAGACC(T/C/ 
G/A)GC(A/G)CT(A/G)CA(G/A)TG-3' correspond to the PTP amino 
acid consensus sequence HCSAG. PCR was performed with the pri-
mer sets Fl+Bl, F2+B2, and F1+B3. QUICK-Clone cDNA prepara-
tions (Clontech) from human skeletal muscle, endothelial cells, liver 
and fat were used as templates. 
Three nanograms of cDNA were used in PCR reactions with 100 
pmoles of each of the above primers for each primer set. The PCR 
reactions were performed in a 100 ul volume using GeneAmp (Perkin 
Elmer Cetus). The reaction mixture was heated to 95°C for 4 min, and 
then subjected to 3 cycles under the following conditions: 95°C for 
1 min, 37°C for 2 min, and 72°C for 3 min, 5 cycles under the 
following conditions: 95°C for 1 min, 42°C for 2 min, and 72°C for 
3 min, 5 cycles under the following conditions: 95°C for 1 min, 47°C 
for 2 min, and 72°C for 3 min, and finally 27 cycles under the follow-
ing conditions: 95°C for 1 min, 53°C for 2 min, and 72°C for 3 min. 
The reaction mixture was subjected to gel electrophoresis on a 1.5% 
agarose gel and 0.4 kb DNA fragments isolated. After digestion with 
BamHl and EcoRI for primer sets (Fl+Bl) and (F2+B2) or with 
BamHI and Xbal for primer set (F1+B3), ligation to the 2.8 kb Bam-
HI-iicoRI or BamHl-Xbal fragment of plasmid pTZ19R (Pharmacia) 
was performed, followed by transformation of a competent E. coli 
strain (r~, m+). Plasmids from the resulting colonies were sequenced 
using Sequenase (U.S. Biochemicals). The results are presented in 
Table 1. 
2.2. Multiprobe RNase protection assay 
Total RNA from human skeletal muscle, liver and placenta were 
commercial preparations (Clontech). Total RNA from cultured hu-
man vascular endothelial cells (HUVEC) was prepared using 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
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RNAgents Total Isolation System (Promega). Human adipose tissue 
total RNA was a kind gift from Per B. Jensen, Novo Nordisk. 
Template DNAs were prepared as previously described in detail [8]. 
In short, templates from the various PTPs were isolated from cDNA 
in which the PTPs had been identified by PCR as described above, 
using specific primers designed from the known DNA sequences and 
standard PCR techniques. The template DNA was cloned into the 
plasmid pGEM-7Zf(+) (Promega) as Hindlll-Xbal fragments, such 
that transcription from the T7 RNA polymerase promoter would 
produce the corresponding PTP antisense riboprobe containing an 
additional 36-38 ribonucleotides at the ends to be removed during 
the ribonuclease protection step. The template plasmids were linear-
ized by Hindlll digestion, purified and then mixed at a final concen-
tration of 4 ng/uj of each template in two sets as indicated in Table 2. 
Three (il of each of the two template sets were labelled for 60 min at 
37°C with 32P-UTP in a total volume of 15 |j.l transcription mixture 
(40 mM Tris-HCl, pH 7.5, 6 mM MgCl2, 2 mM spermidine, 10 mM 
NaCl, 0.47 mM each of GTP, ATP, and CTP, 9.4 uM UTP, 4.7 uM 
[oc-32P]-UTP (3000 Ci/mmol, 10 mCi/ml, DuPont NEN), 10 mM 
DTT, 14 u RNasin ribonuclease inhibitor (Promega) and 24 u T7 
RQ1 RNA polymerase (Promega). The DNA templates were removed 
by addition of 3 u of RQ1 RNase-free DNase (Promega) followed by 
incubation for 30 min at 37°C. After extraction with phenol and 
chloroform, the labelled riboprobe sets were precipitated with ammo-
nium acetate and ethanol and dissolved in hybridization buffer (80% 
formamide, 40 mM PIPES, pH 6.7, 0.4 M NaCl, 1 mM EDTA) at a 
concentration of 2X 106 cpm/ul. 
As an internal control for expression levels, a ribosomal protein 
L32 riboprobe was similarly prepared. Due to the relatively high 
concentration of L32 mRNA in all the tissues and cells examined 
the L32 riboprobe was prepared with 12 times less specific activity 
of a-32P-UTP than the PTP riboprobe set. The L32 probe was dis-
solved at a concentration of 1 X 105 cpm/ul and mixed with equal 
volumes of each of the two PTP riboprobe sets. 
Two u,l of labelled probe set were added to 3 jj.1 hybridization buffer 
containing 5 ug total RNA from human skeletal muscle, endothelial 
cells, adipose tissue, liver, or placenta. Hybridization was at 56°C 
overnight. The mixture was treated with 0.25 |xg RNase A (Boeh-
ringer) and 0.25 u RNase Tl (Life Technologies) at 30°C for 60 
min in 50 ul RNase buffer (10 mM Tris-HCl, pH 7.5, 300 mM 
NaCl, 5 mM EDTA). Then 5 ul of 6% SDS containing 12 ug protei-
nase K (Boehringer) was added, and the mixture incubated at 37°C 
for 30 min. After extraction with phenol and chloroform, 5 ug of 
yeast tRNA was added as a carrier, and the protected RNA precipi-
tated from ammonium acetate with ethanol and then subjected to 
electrophoresis on a standard sequencing polyacrylamide gel. The 
dried gel was placed on a Phosphorlmager screen (Molecular Dynam-
ics) for 3 days. The screen was scanned and bands analyzed by the 
ImageQuant software (Molecular Dynamics) by rectangle mode and 
volume integration. Semi-quantification in relation to the L32 band 
was performed after normalization for uridine content and correction 
for the lower specific activity of the L32 probe. 
2.3. Northern blot analysis 
The 211 bp Hindlll-Xbal DNA fragment from the LARiexon 13 
riboprobe template plasmid described above was labelled with a-32P-
dCTP (Megaprime Labelling System, Amersham). The probe will hy-
bridize to LAR mRNA independently of the presence or absence of 
exon 13. 
107 cpm of labelled probe was hybridized to a Northern blot of 
mRNA from human tissues (Human MTN Blot, Clontech) in 5 ml of 
ExpressHyb hybridization solution for 1 h at 68°C. The blot was 
washed three times 15 min at room temperature in 2XSSC, 0.05% 
SDS and finally twice for 20 min at 50°C in O.lxSSC, 0.1% SDS. 
Autoradiography was performed with intensifying screen at — 70°C 
for 5 h and 10 h. As a control the MTN blot was stripped for the 
LAR probe and reprobed with a beta-actin probe under similar con-
ditions as above. 
3. Results 
3.1. PTPs identified by PCR in the major insulin target tissues 
The expression of PTPs in the major insulin target tissues 
was analyzed with PCR. To obtain a representative picture, 
we attempted to minimize the bias commonly observed with 
P C R by using three different primer sets corresponding to 
conserved regions of known PTPs. As seen in Table 2, signifi-
cant differences were observed between the four tissues. A 
Table 1 
Number of specific PTP clones obtained by PCR on cDNA from the indicated human tissues 
PTP Endothel. cells Liver Skeletal muscle Fat 
Receptor-type PTPases 
PTP-ce 8 
PTP-E 21 
LAR 36 
PTP-o- 2 
PTP-S 12 
PTP-K 7 
PTP-u 2 
PCP-2 1 
CD45 
PTP-y 1 
PTP-ß 32 
DEP-1 
SAP-1 
S31 
Intracellular PTPases 
27 18 
42 
2 
3 
3 
3 
8 
4 
21 
1 
2 
1 
4 
2 
29 
3 
2 
33 
62 
1 
15 
5 
4 
20 
3 
29 
3 
1 
28 
PTP-IB 
T-cell PTP 
BAS 
MEGI 
PTP-Hl 
PTP-D1 
PTP-D2 
SHP-1 
PEST 
MEG2 
7 
2 
38 
7 
2 
1 
1 
3 
!0 
2 
3 
2 
3 
10 
1 
4 
4 
84 
4 
2 
5 
3 
2 
1 
4 
1 
38 
4 
1 
6 
5 
The PTPs are grouped in families based on sequence homology. The primer sets do not allow detection of SHP-2. The total number of PTP clones 
were: 174 from endothelial cells, 158 from liver, 211 from skeletal muscle and 246 from fat cDNA. 
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be a positive regulator of the insulin signal. SHP-2 was found 
to be expressed in all four tissues using specific primers (data 
not shown) and with RNase protection assay (see below). 
Results obtained with the conventional PCR method are 
not quantitative. Therefore, the number of clones do not in-
dicate the relative expression levels of PTPs within a partic-
ular tissue. However, we believe that our approach with three 
different primer sets allows identification of a specific, 'classi-
cal' PTP in a particular tissue unless the expression level is 
extremely low. In this context, it appears significant that PTP-
e is almost exclusively expressed in endothelial cells, and S31 
in fat only, whereas PTP-LAR is not observed in skeletal 
muscle. In a similar PCR experiment, using human skeletal 
muscle cDNA from an independent source, the lack of LAR 
was also observed (data not shown). 
Fig. 1. Multiprobe ribonuclease protection assay (MRPA) using 
probe set I and II (see Table 2) with the L32 ribosomal protein 
probe as an internal reference. 
total of 24 different PTPs were identified. Twelve of these were 
found in all four tissues. Two PTPs, S31 and SAP-1, were 
identified in fat only. It should be noted that the primer sets 
used do not allow identification of SHP-2 which is thought to 
3.2. Multiprobe ribonuclease protection assay (MRPA) 
To obtain semi-quantitative measures we employed our 
multiprobe ribonuclease protection assay protocol [8] on total 
RNA from the major insulin target tissues (Figs. 1 and 2). 
Probes were prepared for 20 of the PTPs identified with PCR 
(Table 1). Special attention was given to PTPs claimed in the 
literature to be involved in regulation of the insulin signal: 
PTP-IB (and the related TC-PTP); PTP-a (and the related 
PTP-e); LAR (and the related PTP-5 and PTP-o); SHP-2 
(and the related SHP-1). Placenta is included as a reference 
tissue representing several different cell types. 
3.2.1. Receptor-type PTPs 
3.2.1.1. PTP-a and PTP-e. These two PTPs are charac-
terized by very short, highly glycosylated extracellular do-
mains. PTP-a is expressed in all four tissues at similar levels, 
whereas PTP-e is mainly expressed in endothelial cells. A 
Table 2 
Riboprobes included in probe sets I and II 
Riboprobe set Size, protect., bases GenBank Ace. no. Residues number 
I 
PTP-a 
PTP-S31 
PTP-IB 
SHP-2 
PTP-a 
LAR exon 13 
LAR all 
PTP-e 
PCP-2 
PTP-K 
PTP-u 
II 
TC-PTP 
DEP1 
MEG1 
SHP-1 
PTP-D2 
PTP-D1 
PTP-y 
PTP-8 
PTP-ß 
CD45 
L32 
407 
361 TM form 
295 
250 
235-
, 325 IC form 
-insert, 220+insert 
205+exon 13, 
171 
154 
146 
133 
119 
320 
265 
240 
220 
200 
180 
160 
140 
120 
100 
78 
190- -exon 13 
U35234 
M31724 
X70766 
M34668 
Y00815 
Y000815 
X54134 
X97198 
Z70660 
X58288 
M25393 
U10886 
M68941 
X62055 
X82676 
X79510 
X54132 
L38929 
X54131 
Y00062 
X03342 
3501-3907 
1101-1395 
1662-1911 
1094-1110/1138-1355 
2666-2870 
5349-5519 
1668-1822 
3021-3166 
2998-3130 
3898-4016 
964-1283 
2941-3205 
1745-1984 
1821-2040 
2871-3070 
2939-3118 
1633-1792 
5611-5750 
5034-5153 
2850-2949 
42-119 
Before hybridization to total RNA the labelled L32 reference probe was added to each of the two labelled probe sets. Prior to RNase protection all 
riboprobes contained an additional 36-38 ribonucleotides at the ends. The LAR exon 13 probe contains the exon 13 sequence, residues no. 2654-
2680. The LAR all probe is directed to the second PTP domain and should detect all splice variants of LAR. The PTP-a riboprobe is able to 
distinguish between the two forms of PTP-a with and without the 9 amino acid insert 3 residues upstream from the TM segment. PTP-S31 is a PTP 
[22] containing a single PTP domain which exists in a receptor type, transmembrane (TM) spanning form as well as in an intracellular (IC) form. 
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Fig. 2. Semi-quantification of PTPs in insulin target tissues from MRPA. The values in % of L32 for LAR—exon 13 are 9.1 for endothelial 
cells, 13.9 for liver, and 15.1 for placenta. For LAR all, the values are 10.2 for liver and 12.7 for placenta. 
splice variant of PTP-cc containing a nine amino acid insert [9] 
was found to be expressed in fat. 
3.2.1.2. PTP-LAR family. In liver and endothelial cells, 
LAR is the most abundantly expressed PTP of the 20 inves-
tigated in the present study. Surprisingly, but in accordance 
with the findings with PCR described above, and the results 
from the Northern blot experiment (Fig. 3), extremely low 
levels of LAR expression are observed in skeletal muscle. 
The same result was observed in separate MRP As with probe 
set I on total RNA from skeletal muscle from two normal 
individuals (data not shown). The splice variant of LAR 
(+exon 13) is mainly expressed in the liver. PTP-8 shows 
very low levels of expression in skeletal muscle and endothe-
lial cells. In contrast, PTP-o is expressed in all four tissues, 
and, in fat, it is the most abundantly expressed of the PTPs 
investigated. 
3.2.1.3. PTP-ß family. The three members analyzed from 
this PTP subfamily have overlapping but distinct tissue distri-
bution patterns. Thus, the recently discovered PCP-2 shows 
relatively high expression levels in skeletal muscle, whereas 
PTP-K is mainly found in liver. PTP-|i is expressed at similar 
levels in all four tissues. 
3.2.1.4. CD45. CD45 is supposed to be exclusively ex-
pressed in hematopoietic cells. Therefore, the low levels of 
expression of CD45 are likely to be caused by contaminating 
blood cells. 
3.2.1.5. PTP-yfamily. These PTPs are characterized by a 
large extracellular domain containing a carbonic anhydrase-
like domain in the N-terminal region. With PCR we observed 
one member of the PTP-y family. Low expression levels of this 
member were observed in all four tissues. 
3.2.1.6. PTP-ß family. In contrast to other receptor-type 
PTPs, this class contains only one intracellular enzyme do-
main [10]. Four members were observed with PCR: PTP-ß, 
DEP-1, SAP-1 and S31. Three of these were analyzed with 
MRPA. Extremely low levels of S31 were detected in all four 
tissues, whereas DEP-1 was a major PTP in liver. PTP-ß was 
abundantly expressed in all tissues analyzed. 
3.2.2. Intracellular PTPs 
3.2.2.1. PTP-1B family. PTP-IB, which is considered to 
Fig. 3. A: Northern blot analysis of LAR expression in various hu-
man tissues. The blot is overexposed in order to show the very faint 
LAR band in skeletal muscle. B: Beta-actin control. 
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be ubiquitously expressed, was found in all tissues with the 
highest levels in endothelial cells. TC-PTP is mainly expressed 
in liver. 
3.2.2.2. Ezrin domain containing PTPs. Five members 
from this family of PTPs were identified with PCR. Three 
of these were analyzed with MRPA. MEG1 and PTP-D1 
were expressed at relatively low levels in all tissues, whereas 
PTP-D2 was a major PTP in endothelial cells and skeletal 
muscle. 
3.2.2.3. SH2 domain containing PTPs. SHP-2 is expressed 
ubiquitously [11]. Relatively high expression levels were ob-
served in liver for SHP-1 which is otherwise believed to be 
expressed in hematopoietic cells only [12]. 
3.3. Northern blot analysis 
The expression of LAR in various human tissues was fur-
ther investigated by Northern blot analysis (Fig. 3). High ex-
pression levels were found in placenta, liver and pancreas, 
medium levels were observed in heart, brain and lung, while 
low levels were present in skeletal muscle and kidney. 
4. Discussion 
The present study was undertaken with the aim of: (a) 
identifying the most abundantly expressed PTPs in the major 
insulin target tissues (using PCR); (b) providing a semi-quan-
titative evaluation of PTP expression in normal tissues. 
Twenty-four different PTPs were identified by PCR and 
significant differences were observed between the different tis-
sues. Most of the differences observed with PCR were con-
firmed with the RNase protection assay. 
We hypothesize that the PTPs involved in the regulation of 
the insulin receptor must be expressed in all major insulin 
target tissues. Previous studies have indicated that PTP-IB 
[13-15], PTP-LAR [16] and PTP-a [17] are negative regulators 
of the insulin receptor tyrosine kinase, and that SHP-2 is a 
downstream positive regulator of the insulin signal. In the 
present study PTP-cc, PTP-IB and SHP-2 were found to be 
expressed at fair levels in all of the main insulin target tissues 
thus supporting earlier studies on the role of these PTPs as 
modulators of the insulin receptor kinase activity. The expres-
sion levels of LAR in skeletal muscle were found to be ex-
tremely low, whereas the highly homologous PTP-o was well 
expressed in all tissues. These results do not seem to support 
the implication of LAR as the main direct modulator of the 
insulin receptor kinase activity in skeletal muscle. 
A series of publications have strongly suggested that PTP-
LAR is a key regulator of the insulin receptor. First, Xhang 
and Goldstein using PCR on rat skeletal muscle cDNA iden-
tified a total of 3 PTPs (PTP-LAR, PTP-oc and CD45) [18]. It 
was confirmed by Northern blotting that PTP-a is expressed 
in rat skeletal muscle. The authors conclude that LAR and 
PTP-a are major PTPs in skeletal muscle, although it was 
noted that skeletal muscle has a relatively low content of 
PTPs compared to liver. Next, by comparing the rate of de-
phosphorylation/inactivation of purified IR by recombinant 
PTP-IB and the cytoplasmic domains of PTP-LAR and 
PTP-a, it was proposed that LAR might play a role in the 
physiological regulation of insulin receptors in intact cells [19]. 
In an attempt to directly identify the PTP(s) involved in reg-
ulation of the IR, Ahmad and Goldstein purified PTPs from 
rat skeletal muscle using the insulin receptor for detection 
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during the purification procedures [20]. Using standardized 
immunoblots PTP-LAR was found to be a predominant 
PTP in skeletal muscle in addition to SHP-2 and PTP-IB, 
although both LAR and PTP-IB were relatively rare proteins 
in skeletal muscle. In contrast to the earlier studies, PTP-a 
was not identified via this approach. To investigate whether 
the obvious discrepancies between these studies and the results 
presented here might be explained by species differences, we 
performed a Northern analysis of rat tissues using a rat LAR 
probe (data not shown). Similar to Northern analysis of hu-
man RNA (Fig. 3), rat skeletal muscle poly A+ RNA gave an 
extremely weak hybridization signal indicating very low ex-
pression levels of LAR. The fact that RNA levels investigated 
in the present work do not necessarily reflect protein levels, 
could explain the discrepancies regarding LAR to some of the 
above mentioned studies. We suggest that a more likely ex-
planation for these discrepancies regarding LAR is that the 
skeletal muscle samples used in the different studies have been 
contaminated to a varying degree with fat tissue, which ex-
presses high levels of LAR (Fig. 2). Further, it has recently 
been found that an increased abundance of PTP-LAR ac-
counts for the elevated insulin receptor dephosphorylating 
activity in adipose tissue from obese human subjects [16]. 
By reducing the level of LAR expression in a rat hepatoma 
cell line through antisense-mediated suppression [21] it was 
found that the insulin-dependent insulin receptor tyrosine kin-
ase activation is increased about 3-fold. However, the epider-
mal growth factor receptor and hepatocyte growth factor-de-
pendent receptor autophosphorylation were similarly 
increased. The present study has shown that LAR is the 
most abundantly expressed PTP among the PTPs studied in 
liver. It is thus not inconceivable that an antisense-mediated 
reduction in the expression level of LAR will result in pro-
nounced effects in a hepatoma cell line. 
Studies on mice deficient in LAR tyrosine phosphatase ac-
tivity have shown defective mammary gland development at 
late pregnancy as the only appreciable phenotype. The mice 
grow and develop otherwise normally, and blood glucose lev-
els are within the normal range (R.Q.J. Schaapveld and W. 
Hendriks, personal communication). These results do not sup-
port the role of LAR as the key regulator of the insulin 
receptor kinase (IRTK). 
We believe that the present study has provided a basic 
framework for further studies of PTPs involved in the insulin 
receptor signal transduction pathway. 
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